Imaging features of triple-negative breast cancers according to androgen receptor status
Authors:
- Rosalind P. CandelariaRCRosalind P. Candelaria
- Beatriz E. AdradaBABeatriz E. Adrada
- Wei WeiWWWei Wei
- Alastair M. ThompsonATAlastair M. Thompson
- Lumarie SantiagoLSLumarie Santiago
- Deanna L. LaneDLDeanna L. Lane
- Monica L. HuangMHMonica L. Huang
- Elsa M. ArribasEAElsa M. Arribas
- Gaiane M. RauchGRGaiane M. Rauch
- W. Fraser SymmansWSW. Fraser Symmans
- Michael Z. GilcreaseMGMichael Z. Gilcrease
- Lei HuoLHLei Huo
- 1 May 2019
- journal article
- research article
- Published by Elsevier in European Journal of Radiology
- Vol. 114, 167-174
Abstract
No abstract availableKeywords
Funding Information
- NIH/NCI
- MD Anderson Cancer Center Breast Cancer Moonshot Program
- CPRIT Multi-Investigator Research Award
This publication has 40 references indexed in Scilit:
- Triple Receptor–Negative Breast Cancer: Imaging and Clinical CharacteristicsAmerican Journal of Roentgenology, 2012
- GSTP1 expression predicts poor pathological complete response to neoadjuvant chemotherapy in ER‐negative breast cancerCancer Science, 2012
- Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working GroupJNCI: Journal of the National Cancer Institute, 2011
- Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapiesJournal of Clinical Investigation, 2011
- Targeting Androgen Receptor in Estrogen Receptor-Negative Breast CancerCancer Cell, 2011
- Triple negative breast cancer - prognostic factors and survivalRadiology and Oncology, 2011
- Triple negative breast cancer: unmet medical needsBreast Cancer Research and Treatment, 2010
- Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast CancerJournal of Clinical Oncology, 2008
- Race, Breast Cancer Subtypes, and Survival in the Carolina Breast Cancer StudyJAMA, 2006
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsThe Lancet, 2005